54997-99-8

Usage

Uses

Used in Veterinary Medicine:
2-NITRO-5-PIPERIDINOANILINE is used as an antimicrobial and antiprotozoal agent for the treatment of infections in farm animals. Its broad-spectrum activity against various pathogens makes it a valuable asset in managing and controlling infections in livestock.
Used in Leishmaniasis Treatment:
In the medical field, 2-NITRO-5-PIPERIDINOANILINE has been explored as a potential treatment for leishmaniasis, a parasitic disease caused by protozoa of the genus Leishmania. Its antiprotozoal properties offer a therapeutic option for managing this disease, although its use is restricted in some countries due to safety concerns.

InChI:InChI=1/C11H15N3O2/c12-10-8-9(4-5-11(10)14(15)16)13-6-2-1-3-7-13/h4-5,8H,1-3,6-7,12H2

Upstream product

• 110-89-4 piperidine 
• 2369-11-1 5-fluoro-2-nitroaniline 
• 1635-61-6 5-chloro-2-nitroaniline 

Downstream Products

• 155198-10-0 2-amino-4-(piperidin-1'-yl)aniline 
• 54998-26-4 2-amino-4-<5'-(piperidin-1''-yl)benzimidazol-2'-yl>aniline 
• 54998-07-1 4-<5'-(piperidin-1''-yl)-1H-benzimidazol-2'-yl>-2-nitroaniline 
• 897446-63-8 2-cyclohexyl-N-(2-nitro-5-piperidin-1-ylphenyl)-2-phenylacetamide 

Relevant academic research and scientific papers

Benzimidazole compound, preparation method thereof and application of the benzimidazole compound in preparation of ferroptosis inhibitor

The invention discloses a benzimidazole compound, a preparation method thereof and application of the benzimidazole compound in preparation of a ferroptosis inhibitor. The benzimidazole compound has a structure as shown in a formula (I) or a formula (II)

Pyrazole spleen tyrosine kinase inhibitor as well as preparation method and application thereof

The invention discloses a pyrazole spleen tyrosine kinase inhibitor, a preparation method thereof, a pharmaceutical composition containing the same, and application of the pyrazole spleen tyrosine kinase inhibitor and the pharmaceutical composition in the preparation of drugs for treating Syk-mediated diseases including cancers, inflammatory diseases and the like.

Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation

Fibroblast growth factor receptor (FGFR) represents an attractive oncology target for cancer therapy in view of its critical role in promoting cancer formation and progression, as well as causing resistance to approved therapies. In this article, we describe the identification of the potent pan-FGFR inhibitor (R)-21c (FGFR1-4 IC50 values of 0.9, 2.0, 2.0, and 6.1 nM, respectively). Compound (R)-21c exhibited excellent in vitro inhibitory activity against a panel of FGFR-amplified cell lines. Western blot analysis demonstrated that (R)-21c suppressed FGF/FGFR and downstream signaling pathways at nanomolar concentrations. Moreover, (R)-21c provided nearly complete inhibition of tumor growth (96.9% TGI) in NCI-H1581 (FGFR1-amplified) xenograft mice model at the dose of 10 mg/kg/qd via oral administration.

Synthesis and biological evaluation of benzimidazole derivatives as potent AMP-activated protein kinase activators

Design, synthesis and structure-activity relationships of benzimidazole derivatives as activators of the AMP-activated protein kinase (AMPK) are presented in this paper. AMPK is the central component of a protein kinase cascade that plays a key role in the regulation of energy balance. Once activated, AMPK initiates a series of responses that are aimed at restoring the energy balance of the cell and recent studies have indicated that AMPK plays an important role in regulation of the whole-body energy metabolism. The following study based on the lead compound S27847 involved modification of three regions of this compound. Preliminary structure-activity relationships are being described.

HETEROCYCLIC KINASE INHIBITORS

Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

DNA Binding Compounds. V. Synthesis and Characterization of Boron-Containing Bibenzimidazoles Related to the DNA Minor Groove Binder, Hoechst 33258

The synthesis and characterization of four novel boron-containing bibenzimidazoles related to the DNA minor groove binder Hoechst 33258 are reported.Such compounds, particularly their 10B-enriched forms, have potential as agents for boron neutron capture therapy which is used in the treatment of cancers.